Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Lei

Showing results (161-170 of 262) with videos related to

Pageof 27
Sort By:
NPJ Breast Cancer|April 14, 2022
LINC00355 regulates p27<sup>KIP</sup> expression by binding to MENIN to induce proliferation in late-stage relapse breast cancerAbdallah M Eteleeb, Prasanth K Thunuguntla, Kyla Z Gelev, et al.
Science Translational Medicine|August 27, 2025
NF1-depleted ER<sup>+</sup> breast cancers are differentially sensitive to CDK4/6 inhibitorsZe-Yi Zheng, Anran Chen, Eric J Jaehnig, et al.
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi = Chinese Journal of Otorhinolaryngology Head and Neck Surgery|August 23, 2019
[Epidemiology of allergic rhinitis in children in grassland of Inner mongolia]T T Ma, Y Zhuang, H Y Shi, et al.
Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery]|October 8, 2021
[Effect of splenectomy on the risk of hepatocellular carcinoma development among patients with liver cirrhosis and portal hypertension: a multi-institutional cohort study]X F Zhang, Y Liu, J H Li, et al.
Cancer Research|October 29, 2021
Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast CancerXuxu Gou, Meenakshi Anurag, Jonathan T Lei, et al.
Cancer Letters|May 30, 2026
NF1 loss in estrogen receptor-positive breast cancer induces osteoclast formation and immunosuppression to promote bone metastasisZifan Zhao, Ze-Yi Zheng, Jonathan T Lei, et al.
Molecular Cancer Therapeutics|May 23, 2024
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast CancerAnran Chen, Beom-Jun Kim, Aparna Mitra, et al.
Cancer Research Communications|July 28, 2023
Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted TreatmentBeom-Jun Kim, Ze-Yi Zheng, Jonathan T Lei, et al.
Oncogene|May 12, 2018
Proteomic profiling identifies key coactivators utilized by mutant ERα proteins as potential new therapeutic targetsLeah A Gates, Guowei Gu, Yue Chen, et al.
Cell Reports. Medicine|August 1, 2025
Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancerMatthew V Holt, Yongchao Dou, Meggie N Young, et al.
Pageof 27

Showing results (161-170 of 262) with videos related to

Sort By:
Pageof 27
NPJ Breast Cancer|April 14, 2022
LINC00355 regulates p27<sup>KIP</sup> expression by binding to MENIN to induce proliferation in late-stage relapse breast cancerAbdallah M Eteleeb, Prasanth K Thunuguntla, Kyla Z Gelev, et al.
Science Translational Medicine|August 27, 2025
NF1-depleted ER<sup>+</sup> breast cancers are differentially sensitive to CDK4/6 inhibitorsZe-Yi Zheng, Anran Chen, Eric J Jaehnig, et al.
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi = Chinese Journal of Otorhinolaryngology Head and Neck Surgery|August 23, 2019
[Epidemiology of allergic rhinitis in children in grassland of Inner mongolia]T T Ma, Y Zhuang, H Y Shi, et al.
Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery]|October 8, 2021
[Effect of splenectomy on the risk of hepatocellular carcinoma development among patients with liver cirrhosis and portal hypertension: a multi-institutional cohort study]X F Zhang, Y Liu, J H Li, et al.
Cancer Research|October 29, 2021
Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast CancerXuxu Gou, Meenakshi Anurag, Jonathan T Lei, et al.
Cancer Letters|May 30, 2026
NF1 loss in estrogen receptor-positive breast cancer induces osteoclast formation and immunosuppression to promote bone metastasisZifan Zhao, Ze-Yi Zheng, Jonathan T Lei, et al.
Molecular Cancer Therapeutics|May 23, 2024
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast CancerAnran Chen, Beom-Jun Kim, Aparna Mitra, et al.
Cancer Research Communications|July 28, 2023
Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted TreatmentBeom-Jun Kim, Ze-Yi Zheng, Jonathan T Lei, et al.
Oncogene|May 12, 2018
Proteomic profiling identifies key coactivators utilized by mutant ERα proteins as potential new therapeutic targetsLeah A Gates, Guowei Gu, Yue Chen, et al.
Cell Reports. Medicine|August 1, 2025
Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancerMatthew V Holt, Yongchao Dou, Meggie N Young, et al.
Pageof 27